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Abstract
Background: The meta-analysis was aimed to compare the long time (> 2 year) clinical 
outcomes of limus-based stents (LBS) and paclitaxel-eluting stents (PES). LBS and PES are 
two kinds of most common coronary artery stents in clinics.
Methods: Electronic data bases of PubMed, Cochrane, and EMBASE were searched. We 
included randomized controlled clinical trials (RCT) comparing LBS and PES with long time 
clinical outcomes. Methodological quality of eligible trials was assessed using “risk of bias” 
tool. The efficacy endpoints included target lesion revascularization (TLR), target vessel reva-
scularization (TVR), and stent thrombosis (ST), and the safety endpoints included all cause 
death, cardiac death, and myocardial infarction (MI). Odds ratios (OR) and 95% confidence 
intervals (95% CI) were calculated for each endpoint.
Results: A total of 23 RCTs and 19,319 participants were included and analyzed in this 
meta-analysis. All trials were of an acceptable quality. At 2 years, LBS showed reduced risk 
of revascularization and ST (TLR: OR = 0.59, 95% CI 0.44–0.78; TVR: OR = 0.63, 95% 
CI 0.55–0.71; ST: OR = 0.55, 95% CI 0.41–0.73) and a lower rate of MI (OR = 0.67, 95% 
CI 0.57–0.79). Subgroup analysis showed that both everolimus-eluting stents and sirolimus-
-eluting stents had better clinical outcomes compared with PES. The comparisons of 3, 4 and 
5 year follow-up results revealed that the clinical outcomes of PES were non-inferior to those 
of LBS but LBS was associated with reduced risk of MI and ST at 3 years.
Conclusions: LBS is associated with better clinical outcomes at 2 years. Both LBS and PES 
showed similar efficacy and safety at long time period. (Cardiol J 2014; 21, 3: 211–219)
Key words: target vessel revascularization, limus-based stents,  
paclitaxel-eluting stents, percutaneous coronary intervention
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Introduction
The application of drug-eluting stents (DES) 
is a landmark event of percutaneous coronary 
intervention (PCI). Compared with bare metal 
stents (BMS), DES is associated with a signifi-
cantly reduced risk of restenosis and target-vessel 
revascularization (TVR) in patients undergoing PCI 
[1, 2]. Although the first generation DES showed 
a perfect solution at the beginning, meta-analysis 
and randomized controlled trials showed that the 
rate of very late (> 1 year) stent thrombosis (ST) 
was increased with first generation DES [3, 4].
Paclitaxel-eluting stents (PES) and sirolimus-
-eluting stents (SES), are recognized as first ge-
neration DES, because they were first introduced 
to the market and approved. Thereafter, a number 
of DES was developed and introduced to the mar-
ket, such as everolimus-eluting stents (EES) and 
zotarolimus-eluting stents (ZES). Generally, limus-
-based stents (LBS) and PES are the two kinds of 
DES most commonly used in clinical. These two 
kinds of coronary stents inhibit in stent reste-
nosis by different pharmacological mechanisms. 
Paclitaxel is an antineoplastic drug interfering cell 
microtubule function [5, 6]. Paclitaxel alters the 
dynamic equilibrium between microtubules and 
alpha- and beta-tubulin by favoring the formation of 
abnormally stable microtubules [7]. In vivo studies 
showed that paclitaxel could inhibit neointimal 
proliferation at a very low blood concentration [8]. 
On the other hand, limus can also inhibit neointimal 
proliferation. Sirolimus is a potent immunosu-
ppressant agent, which induces expression of the 
cyclin-dependent kinase inhibitor, p27 kip1, blocks 
the cell cycle at the G1 to S phase [9]. Everolimus 
can also exert anti-proliferative effect by inhibiting 
cell proliferation and inducing cell cycle arrest in 
the late G1 stage [10].
Given different pharmacological mechanisms, 
the clinical outcomes of PES and LBS may alter 
over time, especially in a long time period. How-
ever, there has been no meta-analysis comparing 
DES with respect to pharmacological mechanisms. 
A lot of meta-analyses have compared the 1 year 
clinical outcomes of SES, EES, and PES [11–13]. 
Thus, we performed this meta-analysis to compare 
the long time (2–5 years) efficacy and safety of the 
LBS and PES in patients with PCI.
Methods
Searching strategy
Electronic databases of PubMed, Cochrane, 
and EMBASE were searched for eligible rando-
mized controlled clinical trials (RCTs). There was 
no limitation on languages and the last search was 
performed on 18 September 2012. The following 
key words were used “sirolimus”, “everolimus”, 
“zotarolimus”, “paclitaxel”, and “stent”. The refe-
rences lists of relative articles were also searched 
for additional trials.
Inclusion and exclusion criteria
Trials met the following inclusion criteria: 
1) RCTs; 2) comparison of LBS and PES in patients 
with PCI; 3) clinical outcomes of 2 years follow-up 
or more. The trials met the following exclusion 
criteria: 1) subgroup results of RCTs; 2) non-
-randomized; 3) without clinical outcomes.
Data collection
Two reviewers independently collected data 
with a standard data-collection form and reached 
consensus on each item. The following data were 
collected: first author, publishing time, stent type, 
time of follow-up, number of participants, age, 
male, number of patients with diabetes, number of 
patients analyzable, target lesion revascularization 
(TLR), TVR, stent thrombosis (ST), all cause de-
ath, cardiac death, and myocardial infarction (MI).
Assessment of risk of bias
The methodological quality of eligible trials 
was assessed using the “risk of bias” tool, recom-
mended by the Cochrane Collaboration. Adequate 
sequence generation, allocation concealment, blin-
ding, incomplete outcome data addressed, and free 
of selective reporting were assessed. Each of the 
5 items was grades as “yes”, “no”, or “unknown”, 
representing “low”, “high”, or “uncertain of ” risk.
Statistical analysis
The efficacy and safety endpoints of LBS and 
PES in this meta-analysis were TLR, TVR, ST, 
all cause death, cardiac death, and MI at 2, 3, 4, 
and 5 years of follow-up. Odds ratios (OR) and 
95% confidence intervals (CI) were calculated 
as summary statistics. Pooled OR was calculated 
using the Mantel-Hænzel fixed effects model or 
DerSimonian-Laird random effects model. In the 
absence of heterogeneity across trials, fixed effects 
model was used, otherwise, we chose random ef-
fects model. The c2 test was performed to test the 
heterogeneity across included trials, and a p < 0.10 
showed a significant heterogeneity. For publication 
bias, a graphic funnel plot was used to detect the 
existence of publication bias. Subgroup analyses 
(SES vs. PES, EES vs. PES, ZES vs. PES) were 
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performed to explore the difference of specific 
type of stents.
Results
Trial flow
A number of 1286 records form databases and 
references lists were screened. After screening of 
titles and abstracts, 82 records were extracted for 
further evaluation. In the end, 23 eligible trials 
[14–36] were included and analyzed. The detailed 
process of trial flow is shown in Figure 1 (flow 
chart).
Characteristics of eligible trials  
and risk of bias
A number of 23 trials and 19319 patients were 
included in our meta-analysis. There were 3 trials 
[14–16] with 5-year clinical outcomes, and 2 trials 
[17, 18] with 4 year-clinical outcomes, 7 trials 
[19–25] with 3 year-outcomes, and 11 trials [26–36] 
with 2 year-clinical results. SES was compared in 
14 trials and EES was compared in 8 trials. Main cha-
racteristics of included trials are shown in Table 1. 
Methodological quality of eligible trials was ac-
ceptable (shown in Table 2). Most trials addressed 
the method for sequence generation and allocation 
concealment.
Clinical outcomes at 2 years
The 2-year follow-up results were available 
in 11 trials with 13251 participants. As for reva-
scularization and ST, LBS was superior to PES at 
2 years. There were 375 patients with LBS and 
406 patients with PES received TLR at 2 years 
of follow-up (OR = 0.59, 95% CI 0.44–0.78; Fig. 2). 
LBS was also associated with lower risk of TVR 
(OR = 0.63, 95% CI 0.55–0.71) and ST (OR = 0.55, 
95% CI 0.41–0.73). In subgroup analysis, both SES 
and EES showed a lower rate TLR and TVR com-
pared with PES, but only EES was associated with 
a reduced risk of ST (OR = 0.33, 95% CI 0.20–0.52). 
In terms of safety, LBS was associated with a lower 
risk of MI (OR = 0.67, 95% CI 0.57–0.79), but LBS 
and PES showed equal results of all-cause death and 
cardiac death. Subgroup analysis revealed that EES 
and ZES reduced the risk of MI but not SES (Table 3).
In conclusion, compared with PES, LBS sho-
wed a lower risk of revascularization and ST at 
2-year follow-up and significantly reduced the 
incidence of MI. As for subgroup analysis, SES and 
EES but not ZES were superior to PES in TLR, 
TVR and ST.
Clinical outcomes at 3 years
A total of 7 trials and 3718 patients were ana-
lyzed for 3-year clinical outcomes. LBS and PES 
had equal clinical outcomes at 3-year follow-up. 
One hundred and twenty-eight and 112 patients 
received TLR at 3 years in the groups of LBS and 
PES, respectively. Patients with LBS had similar 
rate of TLR (OR = 0.80, 95% CI 0.46–1.41; Fig. 3), 
TVR (OR = 0.83, 95% CI 0.66–1.04), and ST 
(OR = 0.78, 95% CI 0.50–1.22) compared to those 
with PES. In subgroup analyses, SES, EES, and 
ZES all showed similar efficacy with PES in the 
comparison of TLR, TVR, and ST. LBS and PES 
did not differ significantly in the rate of all cause 
death (OR = 0.83, 95% CI 0.61–1.14), but LBS was 
associated with lower risk of MI (OR = 0.53, 95% CI 
0.37–0.75). Subgroup analysis showed that only ZES 
showed a reduced risk of MI (OR = 0.43, 95% CI 
0.24–0.79). LBS and PES did not differ significantly 
in most 3-year clinical outcomes, but the rate of MI 
was lower with LBS, especially for ZES (Table 3).
Clinical outcomes at 4 years
Two trials reported 4-year follow-up clini-
cal outcomes of 662 patients. In summary, LBS 
showed lower risk of TLR (OR = 0.53, 95% CI 
0.31–0.92) but similar risk of ST (OR = 1.35, 95% 
CI 0.46–3.98) compared to PES. Both LBS and PES 
showed similar safety, regarding the rate of car-
diac death (OR = 0.58, 95% CI 0.20–1.63) and MI 
(OR = 0.69, 95% CI 0.26–1.84). In the presence of 
only 2 trials, subgroup analysis was not performed. 
LBS was associated a lower rate of TLR compared 
with PES at 4-year follow-up, but they did not differ 
significantly in other clinical outcomes (Table 3).
Figure 1. Flow chart.
Records identified through
database searching
(n = 1158)
Additional records identified
from literature 
(n = 128)
Records screened
(n = 1286)
Records excluded
(n = 1203)
Full-text articles assessed
for eligibility (n = 83) 
Full-text articles
excluded: Subgroup
analysis (n = 17)
Non-randomized
(n = 5)
Not enough follow-up
(n = 38)
Studies included in
qualitative synthesis
(n = 23)
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Table 1. Characteristics of eligible trials.
Author Year Follow up  
[years]
Comparison Patients Age [years] Male Diabetes
Sun-Joo Jang 2012 2 Zotarolimus 
Sirolimus 
Paclitaxel
883 
878 
884
61.7 + 9.3 
61.9 ± 9.6 
62.0 ± 9.6
66.40% 
67.30% 
65.85
30.40% 
28.10% 
27.70%
Lamin King 2012 5 Sirolimus 
Paclitaxel
225 
225
66.8 ± 10.5 
66.6 ± 10.2
75% 
79%
68% 
74%
Ki-Woon Kang 2012 5 Sirolimus 
Paclitaxel
105 
121
60 ± 9 
62 ± 8
34.30% 
43.8%
34.30% 
34.70%
Lorenz Räber 2011 5 Sirolimus 
Paclitaxel
503 
509
62 ± 11 
62 ± 12
76% 
78%
22% 
18%
Gregg W. Stone 2011 2 Everolimus 
Paclitaxel
2458 
1229
63.3 ± 10.5 
63.3 ± 10.2
67.70% 
67.80%
32.00% 
32.50%
Pieter C. Smits 2011 2 Everolimus 
Paclitaxel
897 
903
62.9 
63.6
69% 
72%
17% 
19%
Seung-Whan Lee 2011 4 Sirolimus 
Paclitaxel
200 
200
61.1 ± 8.9 
60.7 ± 8.8
61.00% 
55.00%
100% 
100%
Carlo Briguori 2011 3 Sirolimus 
Everolimus 
Paclitaxel
76 
75 
75
64 ± 8 
65 ± 8 
64 ± 10
57% 
56% 
59%
100% 
100% 
100%
Robert J. Applegate 2011 3 Everolimus 
Paclitaxel
669 
332
63.2 ± 10.5 
62.8 ± 10.2
70.10% 
65.70%
29.60% 
27.90%
Martin B. Leon 2010 3 Zotarolimus 
Paclitaxel
773 
775
64 ± 11 
64 ± 11
66.90% 
68.50%
31.20% 
30.50%
Scot Garg 2011 4 Everolimus 
Paclitaxel
195 
67
62 ± 10 
62 ± 9
71% 
79%
23% 
24%
Soon Jun Hong 2010 3 Sirolimus 
Paclitaxel
85 
84
65.9 ± 8.0 
64.5 ± 8.9
71.80% 
76.20%
100% 
100%
Davran Çiçek 2010 2 Sirolimus 
Paclitaxel
103 
101
57 ± 10.9 
58 ± 10.2
NA 
NA
39% 
36%
Martin B. Leon 2009 2 Zotarolimus 
Paclitaxel
742 
739
63.5 ± 11.1 
63.6 ± 11.0
66.90% 
68.50%
31.20% 
30.50%
Scot Garg 2009 3 Everolimus 
Paclitaxel
195 
69
62 ± 10 
62 ± 9
71% 
79%
23% 
24%
Bimmer E. Claessen 2009 2 Everolimus 
Paclitaxel
211 
73
62 ± 10 
62 ± 9
71% 
79%
23% 
24%
Hyun-Sook Kim 2011 3 Sirolimus 
Paclitaxel
154 
154
60 ± 11 
60 ± 12
76.00% 
76.60%
22.10% 
28.60%
Emilio Di Lorenzo 2009 2 Sirolimus 
Paclitaxel
90 
90
62 ± 15 
63 ± 15
68.90% 
71.10%
23.30% 
27.80%
Julinda Mehilli 2009 2 Sirolimus 
Paclitaxel
305 
302
69.3 ± 9.34 
68.8 ± 10.1
80% 
75%
28% 
30%
Seung-Whan Lee 2009 2 Sirolimus 
Paclitaxel
200 
200
61.1 ± 8.9 
60.7 ± 8.8
61.00% 
55.00%
100% 
100%
Gregg W. Stone 2009 2 Everolimus 
Paclitaxel
642 
309
63.2 ± 10.5 
62.8 ± 10.2
70.10% 
65.70%
29.60% 
27.90%
Michael Billinger 2008 2 Sirolimus 
Paclitaxel
503 
509
NA 
NA
75.90% 
78.4%
100% 
100%
Alexandre Berger 2007 3 Sirolimus 
Paclitaxel
100 
102
65 ± 10 
63 + 10
77% 
83%
NA 
NA
Patients show the number of subjects available for meta-analysis in each trial; age is presented as mean and standard deviate; NA — not available
Clinical outcomes at 5 years
Three trials reported 5-year follow-up results 
of 1688 patients. And 3 trials all compared SES and 
PES, thus, subgroup analysis was not performed. 
There was no statistical difference between the clini-
cal outcomes of LBS and PES at 5 years. They did not 
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Table 2. Risk of bias assessment.
Author Year Adequate 
sequence 
generation
Allocation 
concealment
Blinding Incomplete 
outcome data 
addressed
Free of selective 
reporting
Sun-Joo Jang 2012 Y Y Y Y Y
Lamin King 2012 Y Y Y Y Y
Ki-Woon Kang 2012 Y U Y Y Y
Lorenz Räber 2011 U U U Y Y
Gregg W. Stone 2011 Y Y Y Y Y
Pieter C. Smits 2011 Y Y Y Y Y
Seung-Whan Lee 2011 Y Y Y Y Y
Carlo Briguori 2011 Y Y Y Y Y
Robert J. Applegate 2011 Y Y Y Y Y
Martin B. Leon 2010 Y Y Y Y Y
Scot Garg 2011 Y Y Y Y Y
Soon Jun Hong 2010 Y U Y Y Y
Davran Çiçek 2010 U U U Y Y
Martin B. Leon 2009 Y Y Y Y Y
Scot Garg 2009 U Y Y Y Y
Bimmer E. Claessen 2009 Y Y Y Y Y
Hyun-Sook Kim 2011 Y Y Y Y Y
Emilio Di Lorenzo 2009 Y Y Y Y Y
Julinda Mehilli 2009 Y Y Y Y Y
Seung-Whan Lee 2009 Y Y Y Y Y
Gregg W. Stone 2009 Y Y Y Y Y
Michael Billinger 2008 Y Y Y Y Y
Alexandre Berger 2007 U U Y Y Y
Y for low risk of bias; U for unknown risk of bias
Study of subgroup
Sirolimus
Everolimus
Zotarolimus
Total (95% CI)
Total events
Heterogeneity: Tau2 2 2 = 0.15; Chi  = 33.15, df = 10 (P = 0.0003); I  = 70%
Test for overall effect: Z = 3.67 (P = 0.0002)
Davran Çiçek, 2010
E. Di Lorenzo, 2009
Julinda Mehilli, 2009
Seung-Whan Lee, 2009
M. Billinger, 2008
Sun-Joo Jang, 2012
Subtotal (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 0.34; Chi  = 18.08, df = 4 (P = 0.001); I  = 78%
Test for overall effect: Z = 2.11 (P = 0.03)
B.E. Claessen, 2009
Gregg W. Stone, 2009
Gregg W. Stone, 2011
Pieter C. Smits, 2011
Subtotal (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 0.00; Chi  = 2.10, df = 3 (P = 0.55); I  = 0%
Test for overall effect: Z = 5.36 (P < 0.00001)
Martin B. Leon, 2009
Sun-Joo Jang, 2012
Subtotal (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 0.18; Chi  = 5.03, df = 1 (P = 0.02); I  = 80%
Test for overall effect: Z = 0.25 (P = 0.80)
0
4
30
7
39
20
100
10
39
107
26
182
44
49
93
742
883
1625
34
72
106
7809
375 478
0.1 0.2 0.5 1
Favours experimental Favours control
2 5 10
6122 100.0%
739
884
1623
10.5%
11.5%
22.0%
1.31 [0.83, 2.07]
0.66 [0.46, 0.96]
0.92 [0.47, 1.79]
0.59 [0.44, 0.78]
211
642
2458
897
4208
7
35
82
58
182
73
309
1229
903
2514
5.1%
10.3%
12.5%
10.3%
38.2%
0
90
305
200
503
878
1976
0
5
25
22
66
72
190
0
90
302
200
509
884
1985
3.4%
9.3%
6.1%
11.0%
9.9%
39.7%
Not estimable
0.79 [0.21, 3.05]
1.21 [0.69, 2.11]
0.29 [0.12, 0.70]
0.56 [0.37, 0.86]
0.26 [0.16, 0.44]
0.52 [0.28, 0.95]
0.47 [0.17, 1.28]
0.51 [0.31, 0.82]
0.64 [0.47, 0.86]
0.43 [0.27, 0.70]
0.55 [0.44, 0.69]
Limus Paclitaxel
Events EventsTotal Total Weight
Odds ratio Odds ratio
M-H, random, 95% CI M-H, random, 95% CI
Figure 2. Forest plot for comparison of target lesion revascularization at 2 years. Sizes of data markers are proportional 
to the weight of each study in the meta-analysis. Horizontal bars indicate 95% confidence interval.
Figure 3. Forest plot for comparison of target lesion revascularization at 3 years. Sizes of data markers are proportional 
to the weight of each study in the meta-analysis. Horizontal bars indicate 95% confidence interval.
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Table 3. Meta-analysis results.
Subgroup Target lesion 
revascula- 
rization
Target vessel 
revascula- 
rization
Stent  
thrombus
All death Cardiac death Myocardial  
infarction
2 years 0.59  
[0.44–0.78]
0.63  
[0.55–0.71]
0.55  
[0.41–0.73]
0.90  
[0.73–1.11]
0.92  
[0.68–1.25]
0.67  
[0.57–0.79]
SES vs. PES 0.52  
[0.28–0.95]
0.46  
[0.35–0.60]
0.67  
[0.41–1.10]
0.88  
[0.63–1.23]
0.75  
[0.42–1.33]
0.83  
[0.63–1.09]
EES vs. PES 0.55  
[0.44–0.69]
0.64  
[0.53–0.77]
0.33  
[0.20–0.52]
0.85  
[0.63–1.16]
0.96  
[0.62–1.48]
0.55  
[0.43–0.71]
ZES vs. PES 0.92  
[0.47–1.79]
0.81  
[0.63–1.05]
0.95  
[0.52–1.74]
1.10  
[0.67–1.79]
1.12  
[0.57–2.21]
0.68  
[0.49–0.94]
3 years 0.80  
[0.46–1.41]
0.83  
[0.66–1.04]
0.78  
[0.50–1.22]
0.83  
[0.61–1.14]
NA 0.53  
[0.37–0.75]
SES vs. PES 0.66  
[0.12–3.68]
0.72  
[0.41–1.26]
0.83  
[0.36–1.92]
1.05  
[0.59–1.86]
NA 0.48  
[0.21–1.09]
EES vs. PES 0.81  
[0.34–1.92]
0.78  
[0.53–1.14]
0.83  
[0.34–2.05]
0.63  
[0.36–1.09]
NA 0.65  
[0.39–1.09]
ZES vs. PES 1.10  
[0.72–1.68]
0.91  
[0.65–1.27]
0.72  
[0.38–1.39]
0.88  
[0.53–1.46]
NA 0.43  
[0.24–0.79]
4 years 0.53  
[0.31–0.92]
N/A 1.35  
[0.46–3.98]
N/A 0.58  
[0.20–1.63]
0.69  
[0.26–1.84]
5 years 0.90  
[0.67–1.21]
0.41  
[0.11–1.53]
0.89  
[0.53–1.50]
0.88  
[0.46–1.67]
1.09  
[0.80–1.47]
1.09  
[0.74–1.61]
Results are presented as odds ration and 95% confidence intervals; SES — sirolimus; EES — everolimus; ZES — zotarolimus; PES — paclitaxel; 
NA — not available
Study of subgroup
Sirolimus
Everolimus
Zotarolimus
Soon Jun Hong, 2010
Alexandre Berger, 2007
Carlo Briguori, 2011
Subtotal (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 1.47; Chi  = 5.58, df = 2 (P = 0.06); I  = 64%
Test for overall effect: Z = 0.47 (P = 0.64)
Scot Garg, 2009
Carlo Briguori, 2011
RJ. Applegate, 2011
Subtotal (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 0.41; Chi  = 7.14, df = 2 (P = 0.03); I  = 72%
Test for overall effect: Z = 0.47 (P = 0.64)
Martin B. Leon, 2010
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI)
Total events
2 2 2Heterogeneity: Tau  = 0.29; Chi  = 16.41, df = 6 (P = 0.01); I  = 63%
Test for overall effect: Z = 0.76 (P = 0.45)
2
5
2
9
11
14
46
71
48
48
128
1948 1496 100.0% 0.80 [0.46, 1.41]
112
773
773
44
44
0.02 0.1 1
Favours experimental Favours control
10 50
775
775
24.1%
24.1%
1.10 [0.72, 1.68]
1.10 [0.72, 1.41]
203
75
636
914
7
7
40
54
73
75
312
460
14.9%
15.2%
23.7%
53.8%
85
100
76
261
6
1
7
14
84
102
75
261
8.3%
5.4%
8.4%
22.1%
0.31 [0.06, 1.60]
5.32 [0.61, 46,34]
0.26 [0.05, 1.31]
0.66 [0.12, 3.68]
0.54 [0.20, 1.45]
2.23 [0.84, 5.89]
0.53 [0.34, 0.83]
0.81 [0.34, 1.92]
Limus Paclitaxel
Events EventsTotal Total Weight
Odds ratio Odds ratio
M-H, random, 95% CI M-H, random, 95% CI
differ much regarding the rate of TLR (OR = 0.90, 
95% CI 0.67–1.21; Fig. 4), TVR (OR = 0.41, 95% CI 
0.11–1.53), or ST (OR = 0.89, 95% CI 0.53–1.50). 
In terms of all cause death (OR = 1.09, 95% CI 
0.74–1.61), cardiac death (OR = 0.88, 95% CI 
0.46–1.67), and MI (OR = 1.09, 95% CI 0.80–1.47), 
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no significant difference was found between LBS 
and PES (Table 3). In conclusion, there was no 
significant difference between LBS and PES at 
5-year follow-up.
Heterogeneity and publication bias
Heterogeneity of major comparisons was 
tested and no severe heterogeneity existed ac-
ross trials. Funnel plot of each comparison was 
performed and viewed for symmetry. All of the 
funnel plots were roughly symmetrical (figures 
not shown).
Discussion
This meta-analysis compared long time cli-
nical outcomes of LBS and PES among patients 
undergoing PCI. We included 23 RCTs and 19319 
patients, efficacy and safety of LBS and PES were 
analyzed at 2, 3, 4, and 5-year follow-up.
DES was a breakthrough technology in the 
invasive management of coronary artery diseases. 
LBS and PES are the two most common DES in 
clinical practice. As mentioned before, the neoin-
timal proliferation pharmacological mechanisms 
differ significantly between LBS and PES [8–10]. 
Thus, it is reasonable to hypothesize that LBS 
and PES would have different clinical outcomes, 
especially over a long period of time. Pooled re-
sults from meta-analyses have showed that LBS 
and PES had different efficacy and safety at 1 year 
[11–13], but comparison of long time period was 
rare. This meta-analysis firstly compared clinical 
outcomes of DES in a long time period and most 
importantly, we first compared different types of 
DES according to pharmacological mechanisms. We 
provided a new perspective of comparing coronary 
stents and the long time clinical results would be 
useful for development of new DES.
According to the comparison of 2- to 5-year 
clinical outcomes, we could find that clinical 
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Figure 4. Forest plot for comparison of myocardial infarction at 5 years. Sizes of data markers are proportional to the 
weight of each study in the meta-analysis. Horizontal bars indicate 95% confidence interval.
outcomes of LBS and PES alter with time and 
LBS and PES have equally long time efficacy 
and safety. Previous meta-analyses have showed 
that LBS was associated with lower efficacy, 
such as ST and reintervention, compared with 
PES [11–13]. At 2 years, our meta-analysis 
results of 11 trials suggested that LBS still 
had the advantage over PES in the respect 
of efficacy (TLR, TVR, and ST); additionally, 
LBS was also associated with a reduced risk 
of MI. Subgroup analysis suggested that SES 
and EES significantly reduced the risk of reva-
scularization compared with PES, but ZES was 
not statistically different from PES in most of 
the clinical outcomes. Especially EES was also 
associated with a reduced risk of ST compared 
with PES. At 3 and 5 years of follow-up, LBS and 
PES did not differ significantly in most of the 
clinical outcomes. What is of note is that ZES 
significantly reduced the risk of MI in compari-
son with PES. The 4-year comparison showed 
some discrepancy and we suspected that the 
cause was that too few trials were included.
One important conclusion that can be drawn 
from our meta-analysis is that LBS is non-infe-
rior to PES in terms of very long-time clinical 
outcomes. This adds to our knowledge about 
the longstanding clinical outcomes of stents 
and may change our opinions on the selection 
of stents. Thus far, only SES and EES were 
analyzed as LBS. In the comparisons of 5-year 
clinical outcomes, only trials comparing SES and 
PES were analyzed and trials comparing SES, 
EES and PES were included in the comparison 
of 3 and 4 years.
We also noticed that although LBS and PES 
had similar rate of all-cause death and cardiac 
death, the rate of MI was significantly lower with 
LBS at 2 and 3 years. This may be explained by the 
lower rate of ST in the patients with LBS.
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Limitations of the study
Limitations of this meta-analysis should also 
be noted before the application of the conclusion. 
Firstly, aggregate data were collected from each 
randomized trial and no further subgroup analysis 
could be performed, such as gender, age, smoking 
and other risk factors. Although the characteristics 
of participants of individual study were balanced, it 
was impossible for us to test whether the baseline 
characteristics were balanced between the groups. 
Secondly, trials with 4- and 5-year follow-up were 
rare and this may cause a discrepancy. The 
3 trials analyzed for 5-year clinical outcomes were 
all designed to compare SES and PES, which also 
weakened the representativeness of LBS. Thirdly, 
the meta-analysis was based on randomized trials, 
not individual patient’s data, and we could not as-
sess the confounding factors.
Conclusions
Based on different pharmacological mecha-
nisms, we systematically compared the long time 
clinical outcomes of LBS and PES. We found that 
LBS was associated with better efficacy (TLR, 
TVR, and ST) and lower rate of MI at 2 years, but 
comparisons of long time results revealed that both 
PES and LBS provided similar efficacy and safety. 
This meta-analysis as the first provides a long time 
systematical comparison of 2 different stents and it 
will be useful for future development of new DES.
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